A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy

These data suggest that there is a benefit to front-line pazopanib in patients with STS who are not candidates for cytotoxic chemotherapy.

Source: European Journal of Cancer - July 22, 2020 Category: Cancer & Oncology Authors: Angela C. Hirbe, Vanessa Eulo, Chang I. Moon, Jingqin Luo, Stephanie Myles, Mahesh Seetharam, Jacqui Toeniskoetter, Tammy Kershner, Sasha Haarberg, Mark Agulnik, Varun Monga, Mohammad Milhem, Amanda Parkes, Steven Robinson, Scott Okuno, Steven Attia, Bria Tags: Clinical Trial Source Type: research